JAMA Network
What The Study Did: This study of 1.1 million commercially insured patients with type 2 diabetes investigated whether there are inequities in use of a class of diabetes medications known as glucagon-like peptide-1 receptor agonists (GLP-1 RA) based on race, ethnicity, sex and socioeconomic status.
Authors: Lauren A. Eberly, M.D., M.P.H., of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamahealthforum.2021.4182)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
